- Companies
- Precision Neuroscience
Precision Neuroscience Valuation, Funding & Investors
Precision Neuroscience is valued at $1B as of September 2026.
Last Precision Neuroscience valuation
$1B
Series D · Sep 2026
Last Precision Neuroscience funding round
$250M
Series D · Sep 2026
Cumulative funding Precision Neuroscience raised
$429M
across 4 funding rounds
Key investors in Precision Neuroscience
B Capital
Alumni Ventures
Steadview Capital
Forepont Capital Partners
Korea Investment Partners
Draper Associates
About Precision Neuroscience
Precision Neuroscience is a New York-headquartered developer of brain-computer interface technology. Founded in 2021, it creates minimally invasive, removable cortical implants capable of high-resolution neural recording to treat neurological disorders affecting billions globally.
Founded
2021
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$1B (Sep 2026)
Precision Neuroscience Valuation
Precision Neuroscience is currently valued at $1B, based on its Series D in September 2026. Read the announcement ↗
The $250M round was led by Pershing Square, with participation from Invus, Korea Investment Partners, Duquesne Family Office, Hitachi Ventures, ARK Investment Management and 4 other investors.
Precision Neuroscience's valuation has grown 1.8x from $543M at its Series C in November 2024 to $1B in September 2026, across 2 priced rounds.
Precision Neuroscience valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2026 | Series D | $1B |
| Nov 2024 | Series C | $543M |
Precision Neuroscience Funding History
Precision Neuroscience has raised a total of $429M across 4 funding rounds.
Precision Neuroscience's first fundraising round was a $12M Series A in May 2021. The most recent completed round was a $250M Series D in September 2026.
Precision Neuroscience funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2026 | Series D | Pershing Square (lead); Invus; Korea Investment Partners; Duquesne Family Office; Hitachi Ventures; ARK Investment Management; JSL Health Capital; Mubadala Capital; B Capital; Mirae Asset Capital | $250M | $1B | Precision Neuroscience Corporation closed an oversubscribed Series D financing on September 24, 2026, raising $250 million co-led by Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed leading life sciences investment fund, with additional participation from Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital. The round valued the brain-computer interface company at just over $1 billion and brought total capital raised since its 2021 founding to $430 million. The capital was raised to expand Precision’s clinical program, advance its Layer 7 Cortical Interface through further regulatory review, and build commercialization infrastructure for its brain-computer interface platform. The financing marked the Ackman Oxman Institute’s first disclosed investment and extended backing from a wide group of technology, family office, and life sciences investors across the U.S., Middle East, and Asia. Precision Neuroscience is a New York-based brain-computer interface company developing implantable neural interface technology for medical use. The company was founded in 2021 and had accumulated $430 million in total funding after this round. The transaction was a venture growth equity financing, not a SPAC merger or public-listing transaction. |
| Nov 2024 | Series C | Alumni Ventures (lead); General Equity Holdings (lead) | $126M | $543M | Precision Neuroscience develops minimally invasive, removable brain-computer interfaces (BCI) designed to treat neurological illnesses by enabling paralyzed individuals to control computers with thoughts, positioning itself as a leader in the BCI industry amid growing investor interest. The company announced a $102 million Series C funding round on December 16, 2024, led by General Equity Holdings, with participation from B Capital, Duquesne Family Office, and Steadview Capital, bringing total funding to $155 million. Funds will support clinical research and accelerate development of its AI-powered brain implant. Forge Global lists this Series C at a $542.69 million post-money valuation, with total funding reaching $182.65 million across rounds. Earlier, Precision raised a $41 million Series B led by ForgePoint Capital (noted as Forepont in some sources), with investors including B Capital, Mubadala Capital, Draper Associates, re.Mind Capital, Steadview Capital, and Alumni Ventures. No details found for a $126 million round involving Alumni Ventures and General Equity Holdings around June 11, 2024; investor lists confirm Alumni Ventures in prior rounds but not this specific combination or date. The BCI market is projected to reach $400 billion in the U.S., per Morgan Stanley, with Precision advancing clinical trials and hardware-software innovations. |
| Jan 2023 | Series B | Forepont Capital Partners (lead); Steadview Capital; Alumni Ventures; Mubadala; B Capital; Draper Associates; re.Mind Capital | $41M | - | Precision Neuroscience is a New York City-based brain-computer interface (BCI) company developing high-resolution, minimally invasive, and reversible implants for treating neurological conditions. The company was founded in 2021 by Chief Science Officer Dr. Ben Rapoport, a neurosurgeon and former Neuralink co-founder, and CEO Michael Mager. The company's flagship technology, the Layer 7 Cortical Interface, is an ultra-thin flexible implant approximately one-fifth the thickness of a human hair that conforms to the brain surface without penetrating tissue. The implantation uses a minimally invasive micro-slit surgical approach requiring incisions of only 400 microns in width, differentiating it from more invasive alternatives like Neuralink's craniotomy-based approach. In January 2023, Precision Neuroscience closed a $41 million Series B funding round led by Forepont Capital Partners, with participation from Mubadala Capital, Draper Associates, Alumni Ventures, re.Mind Capital, and existing investors Steadview Capital and B Capital Group. This brought the company's total funding to $53 million within less than two years of founding. The Series B financing was intended to support hiring of specialized talent, advance product development, and facilitate FDA regulatory review, which was expected in the coming months. The company reported positive results from a pilot study of its Layer 7 Cortical Interface in September 2023, demonstrating the technology's capability for high-resolution mapping of brain activity and stimulation. By October 2023, the company raised an additional $93 million in a Series C round, bringing total funding to approximately $146 million at a reported post-money valuation of around $500 million. By March 2026, the company's total funding reached $182.6 million according to secondary sources. |
| May 2021 | Series A | B Capital (lead); Steadview Capital (lead); Forepont Capital Partners | $12M | - | Precision Neuroscience raised $12 million in a Series A financing round on May 25, 2021, led by Steadview Capital and B Capital Group's Ascent Team, along with Forepont Capital Partners. The company develops a platform for next-generation brain-computer interface technology focused on minimally invasive device delivery to address underserved medical needs like paralysis and neurological disorders. The funding supports development of an integrated system of electronics, software, and neural implants, building on nearly two decades of team experience in brain-computer interfaces. Precision Neuroscience aims to deliver life-changing technology to millions of patients worldwide, transforming interactions with machines and addressing large patient populations underserved by current medical technology. The company has offices in New York, California, and Massachusetts. Subsequent rounds include $41 million in February 2023 and additional funding in 2024-2025, bringing total funding over $155 million since 2021. |
Who has invested in Precision Neuroscience?
17 investors have backed Precision Neuroscience across its funding rounds, including B Capital, Alumni Ventures, Steadview Capital, Forepont Capital Partners, Korea Investment Partners and Draper Associates.
Lead investors include Pershing Square, Alumni Ventures, General Equity Holdings, Forepont Capital Partners, B Capital and 1 other investor.
Precision Neuroscience Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | May 2021 | ||
| 2 | Lead | May 2021 | ||
| 2 | Lead | May 2021 | ||
| 2 | Lead | Jan 2023 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Lead | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Sep 2026 | ||
| 1 | Participant | Jan 2023 | ||
This data is available for Pro users. Sign up to see all 17 Precision Neuroscience investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPrecision Neuroscience Competitors
Precision Neuroscience competitors include listed companies like Extreme Vision and Arcs Co, and private ones like Cornerstone Robotics, ZD Medtech, Forterra and Gravis Robotics.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $1B | - | ||
| Private | - | - | $900M | - | ||
| Private | - | $82M | $1B | - | ||
| Private | - | - | $1B | - | ||
| Publicly listed | $44M | ($6M) | $906M | 10.0x | ||
| Publicly listed | $4B | $183M | $1.2B | 0.2x |
Precision Neuroscience Public Comps
Precision Neuroscience is still privately-owned, but its public comps include Kuros Biosciences, Integra Lifesciences, iRadimed, CeriBell, 4DMedical, SI-BONE, Mani Inc., Wandong Medical, Alphatec Holdings and Obsidian Therapeutics.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $146M | $9M | 6.8x | 5.1x | 115.1x | 40.9x | |||
| $1.6B | ($344M) | 0.6x | 0.6x | (2.9x) | 3.1x | |||
| $84M | $28M | 10.9x | 10.1x | 33.3x | 28.5x | |||
| $89M | ($50M) | 10.2x | 8.2x | (18.2x) | (14.3x) | |||
| $5M | ($142M) | 172.6x | 97.2x | (6.0x) | (16.3x) | |||
| $201M | ($17M) | 4.2x | 3.7x | (51.2x) | 69.7x | |||
| $190M | $59M | 4.1x | 3.7x | 13.2x | 9.8x | |||
| $202M | ($46M) | 3.2x | 2.8x | (14.0x) | - | |||
This data is available for Pro users. Sign up to see all Precision Neuroscience competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Precision Neuroscience
| When was Precision Neuroscience founded? | Precision Neuroscience was founded in 2021. |
| Where is Precision Neuroscience headquartered? | Precision Neuroscience is headquartered in New York City, NY, United States. |
| Is Precision Neuroscience publicly listed? | No, Precision Neuroscience is a private, VC-backed company. |
| What is Precision Neuroscience's valuation? | Precision Neuroscience was last valued at $1B in its Series D in September 2026. |
| How much funding has Precision Neuroscience raised? | Precision Neuroscience has raised $429M across 4 funding rounds. |
| What was Precision Neuroscience's last funding round? | Precision Neuroscience's last funding round was a $250M Series D in September 2026, led by Pershing Square. |
| Who are Precision Neuroscience's investors? | Precision Neuroscience's investors include B Capital, Forepont Capital Partners, Steadview Capital, Alumni Ventures, Invus, Korea Investment Partners, Duquesne Family Office, Hitachi Ventures, ARK Investment Management, Pershing Square and 7 others. |
| Which companies are comparable to Precision Neuroscience? | Companies comparable to Precision Neuroscience include Cornerstone Robotics, ZD Medtech, Forterra, Gravis Robotics, Extreme Vision and Arcs Co. |
See companies similar to Precision Neuroscience
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




